GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial

GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial

Item
http://www.wikidata.org/entity/Q30537237
Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesPatient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksDevelopment of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioidsEfficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations.Monitoring complete blood counts and haemoglobin levels in osteoarthritis patients: results from a European survey investigating primary care physician behaviours and understanding.Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice.Management of NSAID-associated peptic ulcer disease.Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study.Characteristics of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-Induced Small Bowel Injury Identified by Single-Balloon Endoscopy or Capsule Endoscopy.Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits.Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice
P2860

GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial

Item
http://www.wikidata.org/entity/Q30537237
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
GI-REASONS: a novel 6-month, p ...... blinded endpoint (PROBE) trial
@ast
GI-REASONS: a novel 6-month, p ...... blinded endpoint (PROBE) trial
@en
type
label
GI-REASONS: a novel 6-month, p ...... blinded endpoint (PROBE) trial
@ast
GI-REASONS: a novel 6-month, p ...... blinded endpoint (PROBE) trial
@en
prefLabel
GI-REASONS: a novel 6-month, p ...... blinded endpoint (PROBE) trial
@ast
GI-REASONS: a novel 6-month, p ...... blinded endpoint (PROBE) trial
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
GI-REASONS: a novel 6-month, p ...... blinded endpoint (PROBE) trial
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932